APP and early-onset autosomal dominant Alzheimer disease: AVE0991 treatment in the APP/PS1 double-transgenic mouse model of Alzheimer’s disease suppressed astrocyte-mediated inflammation by downregulating the expression profile of IL-1β, IL-6, and TNF-α in the brain cortex [42].